StockNews.AI
SOPH
StockNews.AI
182 days

SOPHiA GENETICS to Announce Financial Results for Fourth Quarter and Full Year 2024 on March 4, 2025

1. SOPHiA GENETICS will release Q4 2024 results on March 4, 2025. 2. A conference call will discuss financial results and business outlook. 3. SOPHiA GENETICS specializes in AI-driven data for cancer and rare disorders. 4. The company uses its SOPHiA DDM™ Platform for multimodal data analysis.

Earnings
+21.45%Current Return
VS
+0.51%S&P 500
$4.0102/18 08:35 AM EDTEvent Start
$4.8702/19 03:15 PM EDTLatest Updated
4m saved
Insight
Article

FAQ

Why Bullish?

Positive earnings reports often boost stock prices. Comparable companies see price increases post-results.

How important is it?

Earnings reports significantly influence investor sentiment and stock valuation.

Why Short Term?

Immediate market reactions to earnings could influence SOPH’s stock recently. Historical earnings calls typically show short-term effects.

Related Companies

NDAQ: SOPHNDAQ: AMGNNDAQ: GILD
, /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native software company and a leader in data-driven medicine, today announced it will release its financial results for the fourth quarter and full year 2024 before U.S. markets open on Tuesday, March 4, 2025. On that day, SOPHiA GENETICS will host a conference call to discuss its financial results as well as business outlook beginning at 8:00 a.m. (08:00) EDT / 2:00 p.m. (14:00) CET. The call will be webcast live on the SOPHiA GENETICS Investor Relations Website. Additionally, a replay will be available on the website after its completion. About SOPHiA GENETICS SOPHiA GENETICS (Nasdaq: SOPH) is a software company on a mission to expand access to data-driven medicine by using AI to deliver world-class care to patients with cancer and rare disorders across the globe. It is the creator of the SOPHiA DDM™ Platform, a cloud-native platform that analyzes complex multimodal data – including genomics, radiomics, clinical, biological, and digital pathology data – to generate real-time, actionable insights for a broad global network of hospital, laboratory, and biopharma institutions. For more information, visit SOPHiAGENETICS.COM and connect with us on LinkedIn. SOURCE SOPHiA GENETICS WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In

Related News